KERINS PATRICK J
Known title: 10% OwnerCIK: 0001235112
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Goldman Sachs reinstates Sell rating on SGMT with $7 target. Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.
Transaction History
| BZFD | ▼ Sell | Open Market | 273,246 | $618K | 3/14/2025 | View on chart |
| BZFD | ▼ Sell | Open Market | 61,448 | $124K | 3/13/2025 | View on chart |
| BZFD | ▼ Sell | Open Market | 28,272 | $56K | 3/12/2025 | View on chart |
| BZFD | ▼ Sell | Open Market | 13,629 | $27K | 3/11/2025 | View on chart |
| BZFD | ▼ Sell | Open Market | 33,848 | $70K | 3/7/2025 | View on chart |
| BZFD | ▼ Sell | Open Market | 11,127 | $23K | 3/6/2025 | View on chart |
| BZFD | ▼ Sell | Open Market | 8,966 | $18K | 3/5/2025 | View on chart |
| BZFD | ▼ Sell | Open Market | 1,438 | $3K | 3/4/2025 | View on chart |
| SGMT | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 | View on chart |
| SGMT | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 | View on chart |
| SGMT | ▼ Sell | Other | 850,000 | $0 | 1/29/2024 | View on chart |
| SGMT | ▼ Sell | Other | 13,139 | $0 | 1/29/2024 | View on chart |
| BZFD | ▲ Buy | Option Exercise | 29,034 | $0 | 12/3/2023 | View on chart |
| BZFD | ▲ Buy | Option Exercise | 29,033 | $0 | 9/3/2023 | View on chart |
| BZFD | ▲ Buy | Option Exercise | 29,033 | $0 | 6/3/2023 | View on chart |
| BZFD | ▲ Buy | Option Exercise | 29,033 | $0 | 4/5/2023 | View on chart |
| BZFD | ▲ Buy | Option Exercise | 26,679 | $0 | 12/3/2022 | View on chart |
| BZFD | ▲ Buy | Option Exercise | 26,678 | $0 | 9/3/2022 | View on chart |
| BZFD | ▲ Buy | Option Exercise | 26,678 | $0 | 6/3/2022 | View on chart |
| BZFD | ▲ Buy | Option Exercise | 26,678 | $0 | 3/3/2022 | View on chart |
| BZFD | ▲ Buy | Grant | 15,333,892 | — | 12/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BuzzFeed Features VALITIC™ to Boost Consumer Brand Momentum
BuzzFeed recently highlighted VALITIC™ in a feature titled "Magical Results," which is aimed at reinforcing the company’s consumer brand presence. The coverage showcases how the product aligns with BuzzFeed’s content strategy and may help attract more readers interested in lifestyle and wellness topics. The feature adds another layer of brand association for BuzzFeed, potentially supporting its overall audience engagement.
BuzzFeed Features VALITIC™ to Boost Consumer Brand Momentum. BuzzFeed recently highlighted VALITIC™ in a feature titled "Magical Results," which is aimed at reinforcing the company’s consumer brand presence. The coverage showcases how the product aligns with BuzzFeed’s content strategy and may help attract more readers interested in lifestyle and wellness topics. The feature adds another layer of brand association for BuzzFeed, potentially supporting its overall audience engagement.